ERBB2 and breast carcinoma: Human epidermal growth factor receptor 2 (HER2) overexpression in primary breast cancer is associated with a poor prognosis in 15%–20% of cases, and almost 50% of HER2‐positive breast cancers do not express hormone receptors (HRs) [2].